Decheng Capital’s BioNTech BNTX Stock Holding History

Decheng Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20,000	Closed	-$1.82M	–	26
2025 Q1	$1.82M	Sell	20,000 -20,000	-50%	-$2.24M	0.51%	20
2024 Q4	$4.56M	Buy	+40,000	New	+$4.56M	0.98%	20

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Decheng Capital's BNTX Position: Q2 2025 in Review

Decheng Capital sold out of BioNTech (BNTX) in Q2 2025, closing a stake of 20,000 shares — an estimated $1.82M sold.

Decheng Capital first reported a position in BNTX in Q4 2024 and held it in 2 quarters. The position peaked at $4.56M in Q4 2024. 258 funds tracked by Wall St. Rank hold BNTX as of Q2 2025.

Decheng Capital reported no remaining BioNTech position as of Q2 2025 after selling out during the quarter.
Decheng Capital sold 20,000 BioNTech shares in Q2 2025, an estimated $1.82M.
Decheng Capital first reported a position in BioNTech in Q4 2024 and held it in 2 quarters.
Decheng Capital's BioNTech position peaked at $4.56M in Q4 2024.
258 funds tracked by Wall St. Rank held BioNTech as of Q2 2025.

Based on Decheng Capital's 13F filing for Q2 2025, filed 13 Aug 2025.